Medial EarlySign, a Kfar Malal, Israel-based provider of machine-learning based solutions to improve patient management and non-communicable disease management, completed a $30m Series B financing.
The round, which brings total funding to $50m, was led by aMoon Fund, Marius Nacht’s (Check Point Software Technologies Ltd. Co-founder) investment arm in the life science sector, with participation from Horizons Ventures and Nir Kalkstein.
The company intends to use the funds to further broaden its suite of solutions, and expand clinical research and global implementations of its clinically-supported technology.
Founded in 2009 by Ori Geva, CEO, Medial EarlySign provides an advanced AI-based algorithm platform for healthcare organizations to stratify populations to optimize care for individuals and prevent or delay serious health conditions, by leveraging routine blood test results, and common labs and EHR data. The platform is already in clinical practice, and has been supported by peer-reviewed research published by internationally recognized health organizations and hospitals, including Kaiser Permanente, Oxford University, Maccabi Healthcare Services and others.
The company is developing a suite of AlgoMarker™ stratification models to address a variety of illnesses including cancers, diabetes and associated complications and other life-threatening conditions.